Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA

Emerging Infectious Diseases

Volumn 16, Issue 10, 2010, Pages 1546-1553

  Heysell, Scott K ^a   Moore, Jane L ^b   Keller, Suzanne J ^b   Houpt, Eric R ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b VIRGINIA DEPARTMENT OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG MONITORING; DRUG PROGRAM; DRUG SENSITIVITY; FEMALE; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; TREATMENT RESPONSE; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; COHORT STUDIES; DRUG MONITORING; ETHAMBUTOL; FEMALE; GOVERNMENT PROGRAMS; HUMANS; ISONIAZID; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; VIRGINIA; YOUNG ADULT;

EID: 77958588130     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1610.100374     Document Type: Article

References (30)

1. World Health Organization. Global tuberculosis control: a short update to the 2009 report. 2009 [cited 2010 July 21]. http://www.who.int/tb/publications/global_report/2009/update/en/index.html
2. American Thoracic Society, Centers for Disease Control and Prevention, and Infectious Disease Society of America. Treatment of tuberculosis. MMWR Recomm Rep. 2003;52:1203.
3. Peloquin CA. Pharmacological issues in the treatment of tuberculosis. Ann N Y Acad Sci. 2001;953:157-64. DOI: 10.1111/j.1749-6632.2001.tb11374.x
4. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002;62:2169-83. DOI: 10.2165/00003495-200262150-00001
5. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167:603-62. DOI: 10.1164/rccm.167.4.603
6. Kimerling ME, Phillips P, Patterson P, Hall M, Robinson A, Dunlop NE. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest. 1998;113:1178-83. DOI: 10.1378/chest.113.5.1178
7. Mehta JB, Shantaveerapa H, Byrd RP, Morton SE, Fountain F, Roy TM. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest. 2001;120:1520-4.DOI: 10.1378/chest.120.5.1520
8. Narita M, Hisada M, Thimmappa B, Stambaugh JJ, Ibrahim E, Hollender ES, et al. Tuberculosis recurrence: multivariate analysis of serum levels of tuberculosis drugs, HIV status, and other risk factors. Clin Infect Dis. 2001;32:515-7. DOI: 10.1086/318490
9. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. Determinants of rifampin, isoniazid, pyrazinamide and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother. 2006;50:1170-7. DOI: 10.1128/AAC.50.4.1170-1177.2006
10. Holland DP, Hamilton CD, Weintrob AC, Engemann JJ, Fortenberry ER, Peloquin CA, et al. Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection. Pharmacotherapy. 2009;29:503-10. DOI: 10.1592/phco.29.5.503
11. Patel KB, Belmonte R, Crowe HM. Drug malabsorption and resistant tuberculosis in HIV-infected patients. N Engl J Med. 1995;332:336-7. DOI: 10.1056/NEJM199502023320518
12. Peloquin CA, Nitta AT, Burman WJ, Brudney KF, Miranda-Massari JR, McGuinness ME, et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother. 1996;30:919-25.
13. Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, et al. Isoniazid, rifampin, ethambutol and pyrazinamide pharmacokinetics and treatment outcomes among predominately HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis. 2009;48:1685-94. DOI: 10.1086/599040
14. Chang KC, Leung CC, Yew WW, Kam KM, Yip CW, Ma CH, et al. Peak plasma rifampicin level in tuberculosis patients with slow culture conversion. Eur J Clin Microbiol Infect Dis. 2008;27:467-72. DOI: 10.1007/s10096-007-0454-6
15. American Thoracic Society and the Centers for Disease Control and Prevention. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med. 2000;161:1376-95.
16. Sirgel FA, Fourie PB, Donald PR, Padayatchi N, Rostomjee R, Levin J, et al. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med. 2005;172:128-35. DOI: 10.1164/rccm.200411-1557OC
17. Diacon AH, Patientia R, Venter A, van Helden PD, Smith PJ, McIlleron H, et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother. 2007;51:2994-6. DOI: 10.1128/AAC.01474-06
18. Gelband H. Regimens of less than six months for treating tuberculosis. Cochrane Database Syst Rev. 2000;(2):CD001362.
19. Davies GR, Neurmberger EL. Pharmokinetics and pharmacodynamics in the development of anti-tuberculosis drugs. Tuberculosis (Edinb). 2008;88:S65-74. DOI: 10.1016/S1472-9792(08)70037-4
20. Peloquin C. What is the right dose of rifampin? Int J Tuberc Lung Dis. 2003;7:3-5.
21. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 2008;5:e152. DOI: 10.1371/journal.pmed.0050152
22. Stevenson CR, Forouhi NG, Roglic G, Williams BG, Lauer JA, Dye C, et al. Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence. BMC Public Health. 2007;7:234. DOI: 10.1186/1471-2458-7-234
23. Alisjahbana B, Sahiratmadja E, Nelwan EJ, Purwa AM, Ahmad Y, Ottenhoff THM, et al. The effect of type 2 diabetes on presentation and treatment response in tuberculosis. Clin Infect Dis. 2007;45:428-35. DOI: 10.1086/519841
24. Dooley KE, Tang T, Golub JE, Dorman SE, Cronin W. Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg. 2009;80:634-9.
25. Gwilt PR, Nahhas RR, Tracewell WG. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet. 1991;20:477-90. DOI: 10.2165/00003088-199120060-00004
26. Nijland HMJ, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RHH, et al. Exposure to rifampin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis. 2006;43:848-54. DOI: 10.1086/507543
27. Kenny MT, Strates B. Metabolism and pharmacokinetics of the antibiotic rifampin. Drug Metab Rev. 1981;12:159-218. DOI: 10.3109/03602538109011084
28. Panchagnula R, Agrawal S, Ashokraj Y. Fixed dose combinations for tuberculosis: lessons learned from clinical, formulation and regulatory perspective. Methods Find Exp Clin Pharmacol. 2004;26:703-21. DOI: 10.1358/mf.2004.26.9.872568
29. Malone RS, Fish DN, Spiegel DM, Childs JM, Peloquin CA. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. Am J Respir Crit Care Med. 1999;159:1580-4.
30. Holdiness MR. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet. 1984;9:511-44. DOI: 10.2165/00003088-198409060-00003